Adefovir dipivoxil for wait‐listed and post–liver transplantation patients with lamivudine‐resistant hepatitis B: Final long‐term results

Wait‐listed (n = 226) or post–liver transplantation (n = 241) chronic hepatitis B (CHB) patients with lamivudine‐resistant hepatitis B virus (HBV) were treated with adefovir dipivoxil for a median of 39 and 99 weeks, respectively. Among wait‐listed patients, serum HBV DNA levels became undetectable (<1,000 copies/mL) in 59% and 65% at weeks 48 and 96, respectively. After 48 weeks, alanine aminotransferase (ALT), albumin, bilirubin, and prothrombin time normalized in 77%, 76%, 60%, and 84% of wait‐listed patients, respectively. Among posttransplantation patients, serum HBV DNA levels became undetectable in 40% and 65% at weeks 48 and 96, respectively. After 48 weeks, ALT, albumin, bilirubin, and prothrombin time normalized in 51%, 81%, 76%, and 56% of posttransplantation patients, respectively. Among wait‐listed patients who underwent on‐study liver transplantation, protection from graft reinfection over a median of 35 weeks was similar among patients who did (n = 34) or did not (n = 23) receive hepatitis B immunoglobulin (HBIg). Hepatitis B surface antigen was detected on the first measurement only in 6% and 9% of patients who did or did not receive HBIg, respectively. Serum HBV DNA was detected on consecutive visits in 6% and 0% of patients who did or did not receive HBIg, respectively. Treatment‐related adverse events led to discontinuation of adefovir dipivoxil in 4% of patients. Cumulative probabilities of resistance were 0%, 2%, and 2% at weeks 48, 96, and 144, respectively. In conclusion, adefovir dipivoxil is effective and safe in wait‐listed or posttransplantation CHB patients with lamivudine‐resistant HBV and prevents graft reinfection with or without HBIg. Liver Transpl 13:349‐360, 2007. © 2007 AASLD.

[1]  S. Fan,et al.  Liver transplantation for chronic hepatitis B with lamivudine‐resistant YMDD mutant using add‐on adefovir dipivoxil plus lamivudine , 2005, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[2]  F. Azorin,et al.  Adefovir Dipivoxil Therapy in Liver Transplant Recipients With Lamivudine-Resistant Hepatitis B Virus , 2005 .

[3]  H. Marusawa,et al.  Prevention of hepatitis B virus recurrence after living donor liver transplantation. , 2004, Transplantation proceedings.

[4]  C. Wai,et al.  Adefovir dipivoxil as the rescue therapy for lamivudine-resistant hepatitis B post liver transplant. , 2004, Transplantation proceedings.

[5]  N. Terrault,et al.  Antiviral therapy in patients with chronic hepatitis B and cirrhosis. , 2004, Gastroenterology clinics of North America.

[6]  Wen-Yuan Guo,et al.  Prevention of hepatitis B virus reinfection after orthotopic liver transplantation. , 2004, Hepatobiliary & pancreatic diseases international : HBPD INT.

[7]  S. Ferretti,et al.  Low-dose intramuscular hepatitis B immune globulin and lamivudine for long-term prophylaxis of hepatitis B recurrence after liver transplantation. , 2004, Transplantation proceedings.

[8]  M. Wulfsohn,et al.  Adefovir dipivoxil therapy for lamivudine‐resistant hepatitis B in pre– and post–liver transplantation patients , 2003, Hepatology.

[9]  F. Zoulim.  Treatment of pre‐ and post‐liver transplantation HBV infection: Should we aim at combination therapy? , 2003, Hepatology.

[10]  F. Villamil.  Prophylaxis with anti-HBs immune globulins and nucleoside analogues after liver transplantation for HBV infection. , 2003, Journal of hepatology.

[11]  D. Samuel,et al.  HBV DNA persistence 10 years after liver transplantation despite successful anti‐HBS passive immunoprophylaxis , 2003, Hepatology.

[12]  F. Zoulim.  Towards an improved and cost-saving prophylaxis of hepatitis B virus recurrence after liver transplantation? , 2003, Journal of hepatology.

[13]  M. Buti,et al.  A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation. , 2003, Journal of hepatology.

[14]  M. Brunetto,et al.  Diagnosis and monitoring of hepatitis virus infection in liver transplant patients. , 2003, Transplantation proceedings.

[15]  M. Rizzetto,et al.  Prophylaxis of hepatitis B virus infection before liver transplantation, 1990-2001: a single-center experience. , 2003, Transplantation proceedings.

[16]  F. Mosca,et al.  Impact of antiviral treatment on recurrence of hepatitis B virus infection and disease. , 2003, Transplantation proceedings.

[17]  M. Wulfsohn,et al.  Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. , 2003, The New England journal of medicine.

[18]  C. Gibbs,et al.  Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks , 2002, Hepatology.

[19]  R. Fontana,et al.  Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B , 2002, Liver transplantation.

[20]  T. Berg,et al.  Occurrence and clinical outcome of lamivudine‐resistant hepatitis B infection after liver transplantation , 2001, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[21]  N. Terrault,et al.  Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: A comparative study using a matched, untreated cohort , 2001, Hepatology.

[22]  F. Negro,et al.  Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. , 2001, Journal of hepatology.

[23]  B. Portmann,et al.  Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation. , 2001, Journal of hepatology.

[24]  E. Schiff,et al.  A multicenter United States—Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B , 2001, Hepatology.

[25]  A. Burroughs,et al.  LAMIVUDINE WITHOUT HBIg FOR PREVENTION OF GRAFT REINFECTION BY HEPATITIS B: LONG-TERM FOLLOW-UP , 2000, Transplantation.

[26]  A. Humar,et al.  Lamivudine for hepatitis B in liver transplantation: a single-center experience. , 2000, Transplantation.

[27]  J. Villeneuve,et al.  Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B , 2000, Hepatology.

[28]  M. Manns,et al.  Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under hbig immunoglobulin after liver transplantation , 1999, Hepatology.

[29]  S. Cheung,et al.  Liver Transplantation in Asian Patients With Chronic Hepatitis B Using Lamivudine Prophylaxis , 1999, Annals of surgery.

[30]  E. Schiff,et al.  Multicenter study of lamivudine therapy for hepatitis B after liver transplantation , 1999, Hepatology.

[31]  J. Markmann,et al.  Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin , 1998, Hepatology.

[32]  E. Schiff,et al.  Efficacy of lamivudine in controlling hepatitis B virus recurrence after liver transplantation. , 1998, Transplantation.

[33]  J. Roberts,et al.  Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin , 1996, Hepatology.

[34]  A. Burroughs,et al.  Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis , 1996, The Lancet.

[35]  M. Manns,et al.  Hepatitis B virus envelope variation after transplantation with and without hepatitis B immune globulin prophylaxis , 1996, Hepatology.

[36]  T. Pruett,et al.  Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. , 1996, Transplantation.

[37]  G. Alexander,et al.  Liver transplantation in European patients with the hepatitis B surface antigen. , 1993, The New England journal of medicine.

[38]  D. Samuel,et al.  Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients , 1991, The Lancet.

[39]  R. Pichlmayr,et al.  Long-term immunoprophylaxis of hepatitis B virus reinfection in recipients of human liver allografts. , 1987, Transplantation proceedings.

[40]  S. Cotler,et al.  Management of hepatitis B in liver transplant patients. , 2005, Journal of clinical gastroenterology.

[41]  J. L. Lucena de la Poza,et al.  Adefovir dipivoxil therapy in liver transplant recipients with lamivudine-resistant hepatitis B virus. , 2005, Transplantation proceedings.

[42]  Yao Guang.  Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B in China , 2005 .

[43]  D. Samuel.  Management of hepatitis B in liver transplantation patients. , 2004, Seminars in liver disease.

[44]  E. Albéniz Arbizu,et al.  Use of combined treatment of hepatitis B immune globulin and lamivudine as prevention of hepatitis B virus recurrence in liver allograft. , 2003, Transplantation proceedings.

[45]  S. Davies,et al.  Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications. , 1992, Journal of hepatology.